{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:45:08Z","timestamp":1794584708843,"version":"4.9.1"},"reference-count":88,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Treatment with fluoropyrimidines can lead to cardiotoxicity. For 5-fluorouracil, silent myocardial ischemia and effort-related myocardial ischemia have been demonstrated. We investigated the incidence of myocardial ischemia and clinical cardiotoxicity during treatment with capecitabine, a pro-drug of 5-fluorouracil.\nPatients and methods: We included patients with breast- or colorectal cancer, who received first-time treatment with capecitabine. Holter recording, clinical evaluation, 12-lead electrocardiogram, and measurement of plasma cardiac troponin I and copeptin were performed before and during treatment. \nResults: A total of 42 patients with breast cancer and 39 with colorectal cancer were included. Seven patients (9%) experienced clinical cardiotoxicity; five with unstable angina, one with dyspnoea, ST elevations and anterolateral hypokinesia, and one with cardiac arrest. Six patients (8%) had myocardial ischemia on Holter recording during treatment. Among these were two with clinical cardiotoxicity, and four (5.0%) with silent myocardial ischemia. More patients had myocardial ischemia on Holter recording during treatment compared to before, but the difference was not statistically significant (1st cycle: p = 0.22, 3rd\/4th cycle: p = 0.50). Plasma copeptin increased during 1st cycle (p = 0.004), while cardiac troponin I remained unchanged (p = 0.92). More patients had non-sustained ventricular tachycardia during 1st cycle of treatment than before (p = 0.020).\nInterpretation: Treatment with capecitabine was associated with an incidence of myocardial ischemia of 8%, an incidence of clinical cardiotoxicity of 9%, and an increase in plasma copeptin and the frequency of non-sustained ventricular tachycardia episodes. Increases in cardiac troponin I were rare. The incidence of myocardial ischemia was lower than previously reported for 5-fluorouracil.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.43089","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:28:11Z","timestamp":1751441291000},"page":"837-847","source":"Crossref","is-referenced-by-count":3,"title":["Incidence of myocardial ischemia during treatment with capecitabine: a cohort study with Holter recording and cardiac biomarkers"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-8219","authenticated-orcid":false,"given":"Anne","family":"Dyhl-Polk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-2466","authenticated-orcid":false,"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten K.","family":"Vistisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7993-1016","authenticated-orcid":false,"given":"Anne-Sophie","family":"Sillesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-4133","authenticated-orcid":false,"given":"Stig E.","family":"Bojesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Vaage-Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-8729","authenticated-orcid":false,"given":"Dorte L.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"116870","doi-asserted-by":"crossref","unstructured":"Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"116871","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"116872","doi-asserted-by":"crossref","unstructured":"Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291\u2013305.","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"116873","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2020.06.022","DOI":"10.1016\/j.annonc.2020.06.022"},{"key":"116874","doi-asserted-by":"crossref","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332.","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"116875","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"116876","doi-asserted-by":"crossref","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22\u201340.","DOI":"10.1093\/annonc\/mdx224"},{"key":"116877","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdx224","DOI":"10.1093\/annonc\/mdx224"},{"key":"116878","doi-asserted-by":"crossref","unstructured":"Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2021;32(9):1087\u2013100.","DOI":"10.1016\/j.annonc.2021.06.015"},{"key":"116879","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2021.06.015","DOI":"10.1016\/j.annonc.2021.06.015"},{"key":"116880","doi-asserted-by":"crossref","unstructured":"Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974\u201384.","DOI":"10.1016\/j.ctrv.2013.03.005"},{"key":"116881","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.005","DOI":"10.1016\/j.ctrv.2013.03.005"},{"key":"116882","doi-asserted-by":"crossref","unstructured":"Dyhl-Polk A, Vaage-Nilsen M, Schou M, Vistisen KK, Lund CM, Kumler T, et al. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta Oncol. 2020;59(4):475\u201383.","DOI":"10.1080\/0284186X.2019.1711164"},{"key":"116883","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2019.1711164","DOI":"10.1080\/0284186X.2019.1711164"},{"key":"116884","doi-asserted-by":"crossref","unstructured":"Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer. 2005;41(11):1542\u20136.","DOI":"10.1016\/j.ejca.2005.03.027"},{"key":"116885","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2005.03.027","DOI":"10.1016\/j.ejca.2005.03.027"},{"key":"116886","doi-asserted-by":"crossref","unstructured":"Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol. 2014;25(5):1059\u201364.","DOI":"10.1093\/annonc\/mdu055"},{"key":"116887","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdu055","DOI":"10.1093\/annonc\/mdu055"},{"key":"116888","doi-asserted-by":"crossref","unstructured":"Lestuzzi C, Stolfo D, De Paoli A, Banzato A, Buonadonna A, Bidoli E, et al. Cardiotoxicity from capecitabine chemotherapy: prospective study of incidence at rest and during physical exercise. Oncologist. 2022;27(2):e158\u201367.","DOI":"10.1093\/oncolo\/oyab035"},{"key":"116889","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/oncolo\/oyab035","DOI":"10.1093\/oncolo\/oyab035"},{"key":"116890","doi-asserted-by":"crossref","unstructured":"Dyhl-Polk A, Schou M, Vistisen KK, Sillesen AS, Serup-Hansen E, Faber J, et al. Myocardial ischemia induced by 5-Fluorouracil: a prospective electrocardiographic and cardiac biomarker study. Oncologist. 2021;26(3):e403\u201313.","DOI":"10.1002\/onco.13536"},{"key":"116891","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/onco.13536","DOI":"10.1002\/onco.13536"},{"key":"116892","doi-asserted-by":"crossref","unstructured":"Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J. Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care. Clin Chem. 2017;63(1):73\u201381.","DOI":"10.1373\/clinchem.2016.255109"},{"key":"116893","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1373\/clinchem.2016.255109","DOI":"10.1373\/clinchem.2016.255109"},{"key":"116894","doi-asserted-by":"crossref","unstructured":"Body R, Carlton E. Understanding cardiac troponin part 1: avoiding troponinitis. Emerg Med J. 2018;35(2):120\u20135.","DOI":"10.1136\/emermed-2017-206812"},{"key":"116895","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/emermed-2017-206812","DOI":"10.1136\/emermed-2017-206812"},{"key":"116896","doi-asserted-by":"crossref","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"116897","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad191","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"116898","doi-asserted-by":"crossref","unstructured":"Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol. 2013;10(11):623\u201334.","DOI":"10.1038\/nrcardio.2013.129"},{"key":"116899","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrcardio.2013.129","DOI":"10.1038\/nrcardio.2013.129"},{"key":"116900","unstructured":"Holubec L, Jr., Topolcan O, Finek J, Salvet J, Svoboda T, Svobodova S, et al. Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients \u2013 a pilot study. Anticancer Res. 2007;27(4A):1883\u20136."},{"key":"116901","doi-asserted-by":"crossref","unstructured":"Ceyhan C, Meydan N, Barutca S, Tekten T, Onbasili AO, Ozturk B, et al. Ultrasound tissue characterization by integrated backscatter for analyzing Fluorouracil induced myocardial damage. Echocardiography. 2005;22(3):233\u20138.","DOI":"10.1111\/j.0742-2822.2005.03169.x"},{"key":"116902","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.0742-2822.2005.03169.x","DOI":"10.1111\/j.0742-2822.2005.03169.x"},{"key":"116903","doi-asserted-by":"crossref","unstructured":"Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol. 2004;34(5):262\u20138.","DOI":"10.1093\/jjco\/hyh047"},{"key":"116904","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jjco\/hyh047","DOI":"10.1093\/jjco\/hyh047"},{"key":"116905","doi-asserted-by":"crossref","unstructured":"Salepci T, Seker M, Uyarel H, Gumus M, Bilici A, Ustaalioglu BB, et al. 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels. Med Oncol. 2010;27(2):416\u201320.","DOI":"10.1007\/s12032-009-9226-8"},{"key":"116906","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12032-009-9226-8","DOI":"10.1007\/s12032-009-9226-8"},{"key":"116907","doi-asserted-by":"crossref","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112\u20139.","DOI":"10.1373\/clinchem.2005.060038"},{"key":"116908","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1373\/clinchem.2005.060038","DOI":"10.1373\/clinchem.2005.060038"},{"key":"116909","doi-asserted-by":"crossref","unstructured":"Mu D, Ma C, Cheng J, Zou Y, Qiu L, Cheng X. Copeptin in fluid disorders and stress. Clin Chim Acta. 2022;529:46\u201360.","DOI":"10.1016\/j.cca.2022.02.002"},{"key":"116910","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cca.2022.02.002","DOI":"10.1016\/j.cca.2022.02.002"},{"key":"116911","doi-asserted-by":"crossref","unstructured":"Mueller C, M\u00f6ckel M, Giannitsis E, Huber K, Mair J, Plebani M, et al. Use of copeptin for rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2018;7(6):570\u20136.","DOI":"10.1177\/2048872617710791"},{"key":"116912","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/2048872617710791","DOI":"10.1177\/2048872617710791"},{"key":"116913","doi-asserted-by":"crossref","unstructured":"Parizadeh SM, Ghandehari M, Parizadeh MR, Ferns GA, Ghayour-Mobarhan M, Avan A, et al. The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective. J Cell Biochem. 2018;119(10):7913\u201323.","DOI":"10.1002\/jcb.27093"},{"key":"116914","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/jcb.27093","DOI":"10.1002\/jcb.27093"},{"key":"116915","doi-asserted-by":"crossref","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"116916","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"116917","unstructured":"Product specifications: Thermo scientific BRAMS Copeptin proAVP: Thermo Fischer Scientific. [cited 2025 May 27]. Available from: https:\/\/www.copeptin.com\/images\/downloads\/pdf\/data-sheet-copeptin-proavp-kryptor.pdf"},{"key":"116918","doi-asserted-by":"crossref","unstructured":"Vater LB, Lefebvre B, Turk A, Clasen SC. Fluoropyrimidine cardiotoxicity: incidence, outcomes, and safety of rechallenge. Curr Oncol Rep. 2022;24(7):943\u201350.","DOI":"10.1007\/s11912-022-01256-6"},{"key":"116919","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11912-022-01256-6","DOI":"10.1007\/s11912-022-01256-6"},{"key":"116920","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13(3):484\u20135.","DOI":"10.1093\/annonc\/mdf108"},{"key":"116921","doi-asserted-by":"crossref","unstructured":"Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75\u201382.","DOI":"10.1007\/s00432-007-0250-9"},{"key":"116922","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00432-007-0250-9","DOI":"10.1007\/s00432-007-0250-9"},{"key":"116923","doi-asserted-by":"crossref","unstructured":"Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291\u20137.","DOI":"10.1007\/s002800050043"},{"key":"116924","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s002800050043","DOI":"10.1007\/s002800050043"},{"key":"116925","unstructured":"Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203\u20136."},{"key":"116926","doi-asserted-by":"crossref","unstructured":"Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85\u2013104.","DOI":"10.2165\/00003088-200140020-00002"},{"key":"116927","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00003088-200140020-00002","DOI":"10.2165\/00003088-200140020-00002"},{"key":"116928","doi-asserted-by":"crossref","unstructured":"Forslund L, Hjemdahl P, Held C, Eriksson SV, Bjorkander I, Rehnqvist N. Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]). Am J Cardiol. 1999;84(10):1151\u20137.","DOI":"10.1016\/S0002-9149(99)00526-3"},{"key":"116929","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s0002-9149(99)00526-3","DOI":"10.1016\/S0002-9149(99)00526-3"},{"key":"116930","doi-asserted-by":"crossref","unstructured":"Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF. Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J. 2005;26(14):1402\u20139.","DOI":"10.1093\/eurheartj\/ehi169"},{"key":"116931","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/eurheartj\/ehi169","DOI":"10.1093\/eurheartj\/ehi169"},{"key":"116932","doi-asserted-by":"crossref","unstructured":"Chaulin AM. False-positive causes in serum cardiac troponin levels. J Clin Med Res. 2022;14(2):80\u20137.","DOI":"10.14740\/jocmr4664"},{"key":"116933","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.14740\/jocmr4664","DOI":"10.14740\/jocmr4664"},{"key":"116934","doi-asserted-by":"crossref","unstructured":"Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142(9):786\u201391.","DOI":"10.7326\/0003-4819-142-9-200505030-00015"},{"key":"116935","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7326\/0003-4819-142-9-200505030-00015","DOI":"10.7326\/0003-4819-142-9-200505030-00015"},{"key":"116936","doi-asserted-by":"crossref","unstructured":"Yilmaz U, Oztop I, Ciloglu A, Okan T, Tekin U, Yaren A, et al. 5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring. Int J Clin Pract. 2007;61(5):795\u2013801.","DOI":"10.1111\/j.1742-1241.2007.01323.x"},{"key":"116937","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01323.x","DOI":"10.1111\/j.1742-1241.2007.01323.x"},{"key":"116938","doi-asserted-by":"crossref","unstructured":"Rezkalla S, Kloner RA, Ensley J, al-Sarraf M, Revels S, Olivenstein A, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol. 1989;7(4):509\u201314.","DOI":"10.1200\/JCO.1989.7.4.509"},{"key":"116939","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.1989.7.4.509","DOI":"10.1200\/JCO.1989.7.4.509"},{"key":"116940","doi-asserted-by":"crossref","unstructured":"Abiodun AT, Ju C, Welch CA, Lai J, Tyrer F, Chambers P, et al. Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer. JACC CardioOncol. 2025;7(4):345-56.","DOI":"10.1016\/j.jaccao.2025.01.019"},{"key":"116941","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.01.019","DOI":"10.1016\/j.jaccao.2025.01.019"},{"key":"116942","doi-asserted-by":"crossref","unstructured":"Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J. 1991;12(3):468\u201370.","DOI":"10.1093\/oxfordjournals.eurheartj.a059919"},{"key":"116943","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a059919","DOI":"10.1093\/oxfordjournals.eurheartj.a059919"},{"key":"116944","doi-asserted-by":"crossref","unstructured":"Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11(1):46\u20139.","DOI":"10.1177\/107327480401100107"},{"key":"116945","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/107327480401100207","DOI":"10.1177\/107327480401100207"},{"key":"116946","doi-asserted-by":"crossref","unstructured":"Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, et al. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS One. 2022;17(4):e0265767.","DOI":"10.1371\/journal.pone.0265767"},{"key":"116947","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0265767","DOI":"10.1371\/journal.pone.0265767"},{"key":"116948","doi-asserted-by":"crossref","unstructured":"Rajiah PS, Fran\u00e7ois CJ, Leiner T. Cardiac MRI: state of the art. Radiology. 2023;307(3):e223008.","DOI":"10.1148\/radiol.223008"},{"key":"116949","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1148\/radiol.223008","DOI":"10.1148\/radiol.223008"},{"key":"116950","doi-asserted-by":"crossref","unstructured":"Juneau D, Erthal F, Ohira H, Mc Ardle B, Hessian R, deKemp RA, et al. Clinical PET myocardial perfusion imaging and flow quantification. Cardiol Clin. 2016;34(1):69\u201385.","DOI":"10.1016\/j.ccl.2015.07.013"},{"key":"116951","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ccl.2015.07.013","DOI":"10.1016\/j.ccl.2015.07.013"},{"key":"116952","doi-asserted-by":"crossref","unstructured":"Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487\u201393.","DOI":"10.1007\/s00280-005-0178-1"},{"key":"116953","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00280-005-0178-1","DOI":"10.1007\/s00280-005-0178-1"},{"key":"116954","doi-asserted-by":"crossref","unstructured":"Lanza GA, Mascellanti M, Placentino M, Lucente M, Crea F, Maseri A. Usefulness of a third Holter lead for detection of myocardial ischemia. Am J Cardiol. 1994;74(12):1216\u20139.","DOI":"10.1016\/0002-9149(94)90551-7"},{"key":"116955","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0002-9149(94)90551-7","DOI":"10.1016\/0002-9149(94)90551-7"},{"key":"116956","doi-asserted-by":"crossref","unstructured":"Stagmo M, Juul-Moller S, Israelsson B. Fifteen-year risk of major coronary events predicted by Holter ST-monitoring in asymptomatic middle-aged men. Eur J Cardiovasc Prev Rehabil. 2005;12(5):478\u201383.","DOI":"10.1097\/01.hjr.0000176511.22284.c1"},{"key":"116957","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/01.hjr.0000176511.22284.c1","DOI":"10.1097\/01.hjr.0000176511.22284.c1"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43089\/50642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43089\/50642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:02:40Z","timestamp":1756404160000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/43089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":88,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.43089","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}